A Randomised, Parallel-Arm, Open-Label Trial Comparing Degarelix With Goserelin Plus Anti-Androgen Flare Protection (Bicalutamide), in Terms of Reduction in International Prostate Symptom Score (IPSS), in Patients With Lower Urinary Tract Symptoms (LUTS) Secondary to Locally Advanced Prostate Cancer

Trial Profile

A Randomised, Parallel-Arm, Open-Label Trial Comparing Degarelix With Goserelin Plus Anti-Androgen Flare Protection (Bicalutamide), in Terms of Reduction in International Prostate Symptom Score (IPSS), in Patients With Lower Urinary Tract Symptoms (LUTS) Secondary to Locally Advanced Prostate Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2014

At a glance

  • Drugs Degarelix (Primary) ; Bicalutamide; Goserelin
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Apr 2014 Results from a pooled analysis presented at the 29th Congress of the European Association of Urology.
    • 13 Feb 2013 German Clinical Trials Register reports actual trial initiation date as 30 Apr 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top